Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


This prospective study was initiated in 1993 with the aim to study late effects and responses to antiviral therapy in a cohort of hepatitis C virus (HCV)-infected patients. A total of 195 patients were included from 12 centers. In all, 134 patients had undergone allogeneic and 61 autologous hematopoietic SCT (HSCT). The median follow-up from HSCT is currently 16.8 years and the maximum 27.2 years. Overall 33 of 195 patients have died of which 6 died from liver complications. The survival probability was 81.6% and the cumulative incidence for death in liver complications was 6.1% at 20 years after HSCT. The cumulative incidence of severe liver complications (death from liver failure, cirrhosis and liver transplantation) was 11.7% at 20 years after HSCT. In all, 85 patients have been treated with IFN; 42 in combination with ribavirin. The sustained response rate was 40%. The rates of severe side effects were comparable to other patient populations and no patient developed significant exacerbations of GVHD. Patients receiving antiviral therapy had a trend toward a decreased risk of severe liver complications (odds ratio=0.33; P=0.058). HCV infection is associated with morbidity and mortality in long-term survivors after HSCT. Antiviral therapy can be given safely and might reduce the risk for severe complications.


  • P. Ljungman
  • A. Locasciulli
  • V. G. de Soria
  • Albert Békássy
  • L. Brinch
  • I. Espigado
  • A. Ferrant
  • I. M. Franklin
  • J. O'Riordan
  • M. Rovira
  • P. Shaw
  • H. Einsele
Enheter & grupper

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Pediatrik


Sidor (från-till)1217-1221
TidskriftBone Marrow Transplantation
StatusPublished - 2012
Peer review utfördJa


Ingen tillgänglig data